达格列净联合利拉鲁肽治疗2型糖尿病伴代谢综合征患者临床疗效

目的 探讨达格列净联合利拉鲁肽治疗2型糖尿病伴代谢综合征患者临床疗效。方法 2型糖尿病伴代谢综合征患者52例,按1∶1随机分为对照组(n=26)与观察组(n=26)。对照组应用利拉鲁肽治疗,观察组在对照组基础上联合达格列净治疗。疗程为12周,比较两组治疗前后相关指标变化。结果 治疗后,两组血糖代谢指标、胰岛功能指标、体重指数、腰围、血压及血脂代谢均较治疗前明显改善(P<0.05)。治疗后,观察组空腹血糖、餐后2 h血糖、糖化血红蛋白、胰岛素抵抗指数、体重指数、腰围、收缩压、舒张压、总胆固醇、甘油三酯较对照组明显降低(P<0.05),高密度脂蛋白胆固醇、空腹胰岛素、胰岛β细胞功能指数较对照组明显升高(P<0.05),低密度脂蛋白胆固醇较对照组无明显差异(P>0.05)。治疗期间两组不良反应发生率差异无统计学意义(P>0.05)。结论 达格列净联合利拉鲁肽治疗2型糖尿病伴代谢综合征患者,能有效控制血糖,降低体重、改善肥胖状态,调控血压和血脂代谢,同时减轻胰岛素抵抗和改善胰岛功能,且安全性好。

Clinical efficacy of dapagliflozin combined with liraglutide in the treatment of type 2 diabetes mellitus with metabolic syndrome

Objective To investigate the clinical efficacy of dapagliflozin combined with liraglutide in the treatment of type 2 diabetes mellitus(T2DM) with metabolic syndrome.Methods Fifty-two T2DM patients concurrent with metabolic syndrome were selected and randomly divided into the control group (n=26) and the observation group (n=26), according to 1∶1.The control group was treated with liraglutide, and the observation group was additionally treated with dapagliflozin on the basis of the control group.The course of treatment was 12 weeks. The changes of related indicators were compared before and after treatment in two groups.Results After treatment, the blood glucose metabolism index, islet function index, body mass index, waist circumference, blood pressure, blood lipids in both groups were improved(P<0.05). The levels of fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin, insulin resistance index,body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides in the observation group were significantly decreased compared with the control group after treatment(P<0.05), and high-density lipoprotein cholesterol, fasting insulin and pancreatic β cell function index were significantly increased(P<0.05), while low-density lipoprotein cholesterol had no difference(P>0.05). There was no statistical difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion The combination of dapagliflozin and liraglutide for T2DM concurrent with metabolic syndrome can effectively control blood sugar, reduce weight, improve obesity, regulate blood pressure and lipid metabolism, reduce insulin resistance and improve islet function, and have good safety.